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Background: Machado-Joseph disease (MJD) is an au-
tosomal dominant cerebellar ataxia of adult onset with a
high prevalence in the islands of Azores (Portugal). The
genetic epidemiological studies presently under way in these
islands are based on the genealogical reconstruction of the
affected families, thus partially depending on the refer-
ence of patients using family history. A considerable ef-
fort has been made to obtain genealogies that are as com-
plete as possible, making use of different types of data. The
utility of the death causes contained in the death registers
of the patients with MJD was determined in this study.
Objectives: To estimate the extent to which the cause
of death reported in the death register can confirm other
reports of an individual’s status for the disease (ie, oral
information), and to determine the accuracy of the death
certificates in listing MJD in patients whose disease was
clinically diagnosed.
Design: Case-control study.
Methods: The death registers of 113 patients with MJD
(82 whose disease was identified by history and 31 whose
disease was clinically diagnosed) were examined and com-
pared with those of controls matched by sex and date and
place of death.
Results: There were significant differences in the causes
of death between cases and controls, both for those whose
disease was identified by history (x2= 51.69, P,.001) and
for those whose disease was identified by examination
(x2= 27.78, P = .004). However, the cause of death was
in accord with the presence of the disease in only 40%
of the cases reported as being identified only by family
history. In the cases in which the disease was clinically
diagnosed, only nearly 38% of the registers provided re-
liable information as to MJD being the direct cause of
death.
Conclusions: The fact that only nearly 40% of the pa-
tients with clinically confirmed MJD had a cause of death
compatible with MJD precludes the use of cause of death
as a means of identifying affected individuals in the
Azorean MJD pedigrees.
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M ACHADO-JOSEPH dis-ease (MJD) is a late-onset, progressive,neurodegenerative dis-order that involves the
cerebellar, ocular motor, pyramidal, ex-
trapyramidal, and peripheral motor sys-
tems. The mean age at onset is 40.5 years.
The estimated median survival time is 20
years.1 There is no treatment to delay or
halt the progression of the disease. The
MJD gene, which has been linked to chro-
mosome 14,2 consists of an unstable trip-
let (CAG) expansion at 14q32.1.3
Machado-Joseph disease was first de-
scribed in North American patients who had
emigrated from the Portuguese islands of the
Azores.4-6 For this reason, the disease’s ori-
gin was believed to be Azorean, and the en-
tity was temporarily referred to in the lit-
erature as an “Azorean disease of the
nervous system.”7-9 To date, 34 affected
families have been identified in the Azores,
where the current estimated prevalence of
the disease is 1/2402.10 To understand the
origin and spread of the mutant gene in
these islands, a multidisciplinary research
program was developed that aims to study
MJD from a genetic, epidemiological, and
demographic perspective. The data used for
the analysis were obtained from the data-
base “Willy,” which includes detailed ge-
nealogical and demographic information on
all the Azorean MJD families. These stud-
ies are based on the reconstruction of the
MJD families and therefore rely on the qual-
ity of the genealogies obtained. In similar
studies, the accuracy of the data contained
in the genealogies has proved to be crucial
in understanding the mechanisms respon-
sible for the representation of deleterious
genes in specific populations.11 Therefore,
a considerable effort has been made to ob-
tain MJD genealogies that are as complete
as possible by collecting and making use of
different types of data.
The data contained in death registers
are often criticized, mainly because of their
lack of accuracy.12,13 Our intention, how-
ever, is not to address this issue but to evalu-
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ate whether determining the cause of death can help to de-
tect affected individuals in large MJD Azorean pedigrees.
There were 2 main aims for the analysis. First, we esti-
mated the extent to which the cause of death reported in
the death register could confirm other reports of an indi-
vidual’s having the disease (ie, oral information). This is
an important objective, since one of the problems associ-
ated with the organization of a database for the Azorean
MJD families has been the ascertainment of the disease sta-
tus of the individuals who were reported as being affected
by close relatives but who died without a clinical diagno-
sis. The second aim was to determine the accuracy of the
death certificates in listing MJD in patients whose disease
was clinically diagnosed. The information contained in the
deathcertificates, if provedaccurate, could improve thequal-
ity of the genealogies and therefore allow an estimation of
the prevalence of this disease in past generations, provid-
ing a better understanding of the present epidemiological
situation of MJD in the Azores.
RESULTS
DISTRIBUTION OF DEATH REGISTERS
Thedistributionof the registers analyzed,bydecadeofdeath,
is shown in Figure 1. There was a concentration of the
“disease identified by history” in the period 1961 to 1971.
The cases of clinically confirmed MJD were most frequent
in the period 1971 to 1991. This finding is in accord with
the fact that the disease was not specifically diagnosed un-
til 1972,4 becoming recognizable as a specific clinical en-
tity in the Azores only by the end of the 1970s.15
PROPORTIONAL MORTALITY RATIO
Table 1 presents the proportional mortality ratio in in-
dividuals with MJD (G1 and G2) compared with controls
(C1 and C2, respectively). For the G1 group, category 4 is
clearly the most frequently represented, with 38.7% of the
deaths attributed to a neurological disease. In control group
C1, no death attributed to a neurological cause was re-
ported. Neurological disorders are listed as a cause of death
in only 12 (38.7%) of the 31 clinically confirmed cases of
MJD (G2); there was no death attributed to a neurological
disorder reported in the controls (C2).
DIFFERENCES IN CAUSES OF DEATH
BETWEEN CASES AND CONTROLS
The large value for cardiovascular disorders (second in
rank of occurrence in G1, as shown in Table 1) agrees
with the overall trend in the Azorean population. In con-
trol group C1, heart disease (category 6) is the major cause
of death, which also is in accordance with the general
trend in the population. In this control group, 25.8% of
the registers give no information on the reasons that led
PATIENTS AND METHODS
A list of deceased individuals identified as having had MJD
was obtained from the database on the MJD Azorean fami-
lies (Willy). Willy contains the genealogies of all Azorean MJD
families, consisting of more than 8500 individuals and 3200
unions. The database and the software have been described
in detail elsewhere.10 We selected the affected individuals with
date and cause of death listed in the death register from these
MJD families. The individuals were then classified into 2 dif-
ferent groups: group 1 (G1), individuals who were identi-
fied by close relatives as having had MJD but who died with-
out a clinical diagnosis (disease identified by history); and
group 2 (G2), individuals with clinically confirmed MJD (dis-
ease identified by examination). The diagnosis of MJD was
determined by clinical examination by an experienced neu-
rologist, using established diagnostic criteria.14
Only individuals who died between 1911 and 1990 were
included, since it is only from 1911 on that cause of death
has been registered. In 1990, legislation aiming to ensure the
confidentiality of cause of death was issued, preventing it from
being referred to in the registers. Therefore, because cause
of death stopped being reported in the death registers after
1990, this year defines the upper limit of our study. During
most of the period analyzed, only 1 cause of death is listed.
In the few cases in which more than 1 diagnosis was listed,
we retained the 1 representing the primary cause of death.
The sample analyzed consisted of a group of 82 indi-
viduals (51 men and 31 women) in G1 (disease identified
by history) and a group of 31 individuals (18 men and 13
women) in G2 (disease identified by examination). Data
available from death registers consisted of sex, date of birth,
place of birth, date of death, place of death, and cause of
death (primary cause). The 2 sexes were not considered
separately in the analysis, because the number of individu-
als included was too small to show possible differences be-
tween them. For each individual in G1 and G2, one con-
trol was selected from a group reported as “not affected”
from the same database (Willy), using sex, place of death
(island), and date of death within 10 years as matching vari-
ables. The control individuals consisted of nonaffected in-
dividuals who were part of the large MJD genealogies. These
controls were selected from branches of the MJD families
in which no reference to affected individuals existed, at least
2 generations before the individuals chosen. This method-
ology aimed to decrease the chances of including at-risk
individuals (50% risk) in the control group. Although not
matching for age at death, and considering the fact that MJD
is a late-onset disease, only adults (older than 20 years) were
sampled as controls. The mean ± SD age at death among
those in G1 was 60.3 ± 14.6 years and 53.4 ± 20.3 years
among the controls (C1). The average age at death among
those in G2 was 62.2 ± 13.6 years and 68.4 ± 16.4 years
among the controls (C2).
The causes of death were grouped into 12 general cat-
egories, numerically coded. Although the grouping con-
tained some ambiguity, it was necessary, in view of the vari-
ability of the causes of death. The proportional mortality
ratio (number of deaths from a specific cause over the to-
tal number of deaths) was calculated for cases and con-
trols. A x2 test was used to determine the significance of
the differences in the distribution of causes of death be-
tween cases and controls and between the 2 groups of cases.
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to the individual’s death, either because the description
used was too ambiguous to allow specific classification
(12.9%) or because the cause of death is listed as un-
known (12.9%).
The results of the x2 test are shown in Table 2. We
limited the analysis to individuals who died within the same
time interval (1970-1990) and whose disease was identi-
fied either by history or by examination. There were sta-
tistically significant differences in the distribution of the
causes of death between cases and controls in all 4 groups
(ie, G1 and C1 and G2 and C2). No significant difference
was found between the 2 groups of cases.
CAUSES OF DEATH WITHIN THE
NEUROLOGICAL DISORDERS CATEGORY
The specific causes of death listed in the registers within
category 4 (neurological disorders), for individuals whose
disease was identified by history (38.7% of the cases) and
for those whose disease was identified by examination
(37.8% of the cases), are shown in Figure 2. In G1, ta-
bes, sclerosis, ataxia, and paralysis were almost equally com-
mon.Multiple sclerosiswas reported twiceasa specific cause
of death in G1. No death attributed to MJD was recorded
in this group, since the specific diagnosis could not be made
until the end of the 1970s. On the other hand, in G2, MJD
was the most frequent specific cause of death, followed by
ataxia. No specific reference to multiple sclerosis was made
in this group. Parkinson disease was not listed as a spe-
cific cause of death in either G1 or G2.
OTHER CAUSES OF DEATH
ASSOCIATED WITH MJD
Because the concomitant complications of MJD (eg, bron-
chopneumonia, often due to aspiration caused by dys-
phagia) could be recorded as the cause of death in clini-
cally confirmed cases of MJD,9,14 we would expect that
respiratory diseases would be second in order of occur-
rence in G2. This was not the case in our study, in which
only 4.9% of the patients with clinically confirmed MJD
died of a respiratory complication (Table 1). Other causes
of death known to be associated with MJD, such as de-
cubital ulcer or catheter-related sepsis, were classified
within the infectious diseases group and were also ob-
served at a low frequency (8.5%).
COMMENT
For G1, all the discriminated causes included in the neu-
rological disorders category (Figure 2) are highly compat-
ible with a diagnosis of MJD, ataxia being the most reli-


















Figure 1. Distribution, by decade of death, of the death registers for the 2
groups of cases (identified by history and identified by examination).
Table 1. Proportional Mortality Ratio in Patients












1. Respiratory disease 3.2 9.7 4.9 10.9
2. Cancer 6.5 6.4 3.6 8.5
3. Intestinal disease 0.0 0.0 4.9 10.9
4. Neurological disease 38.7 0.0 37.8 0.0
5. Trauma 0.0 3.2 1.4 4.9
6. Heart disease 3.2 25.8 3.6 15.8
7. Infectious disease 3.2 3.2 8.5 12.2
8. Nonspecified 6.5 12.9 9.7 14.6
9. Bone disease 3.2 0.0 4.9 4.0
10. Stroke 32.3 19.4 8.5 8.5
11. Chronic disease† 3.2 6.5 6.1 1.2
12. Unknown 0.0 12.9 6.1 8.5
*G1 indicates group whose disease was identified by history; C1, control
group for G1; G2, group whose disease was identified by examination; and C2,
control group for G2.
†Other than neurological.
Table 2. Distribution of Cause of Death Categories
Between Patients With Machado-Joseph Disease
and Controls and Between the 2 Groups of Patients
Groups* x2 df P
G1/C1 51.69 11 <.001†
G2/C2 27.78 11 .004†
G1/G2 11.79 11 .38
*G1 indicates group whose disease was identified by history; C1, control
group for G1; G2, group whose disease was identified by examination; and
C2, control group for G2.














Figure 2. Causes of death within category 4 (neurological disorders) for
patients whose disease was identified by history (G1) and for patients whose
disease was identified by examination (G2). CNS indicates central nervous
system; MJD, Machado-Joseph disease.
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diagnosis for dominant ataxias. Tabes dorsalis, although
related to syphilis, was often associated with ataxia in de-
generative disorders. Sclerosis could be related to mul-
tiple sclerosis, a diagnosis that even nowadays is still oc-
casionally made in cases of MJD. Finally, paralysis and
paraplegia possibly describe the motor incapacity in MJD.
We can therefore conclude that an indication of the pres-
ence of the disease could be obtained in approximately 40%
of the patients in G1, this percentage corresponding to the
individuals for whom neurological disorders have been re-
ported as the cause of death.
Regarding the clinically confirmed cases of MJD, 3
groups of causes of death could be compatible with death
occurring as a result of the natural course of the illness (neu-
rological, respiratory, and infectious diseases, in this or-
der of importance). The fact that higher frequencies for the
categories of respiratory diseases or infectious diseases were
observed in the control group leads us to infer that no as-
sociation exists between these groups of causes of death
and MJD. Therefore, we concluded that only 37.8% of the
cases in G2 have a cause of death potentially in accor-
dance with MJD (Table 1); in the remaining cases, no re-
liable indication of the presence of the disease was given.
The clinical variability of MJD can be attributed to the fact
that a reduced proportion of deaths were the result of a neu-
rological disorder. A later form of the disease, correspond-
ing to type 3 described by Coutinho and Andrade,15 dem-
onstrates a slow evolution of symptoms, allowing the
affected individuals to reach a considerable age.16 There-
fore, in patients with type 3 MJD, the registered cause of
death is likely not to be MJD. One additional factor could
be responsible for the nonreporting of MJD as the cause of
death in some cases: if the individuals die of an unrelated
illness (eg, cancer) at the beginning of the natural course
of the disease, it is probable that there will be no reference
to MJD when the cause of death is listed. The fact that sta-
tistically significant differences were found in the distri-
bution of causes of death in the patients with MJD com-
pared with controls seems to indicate that, to some extent,
death causes can be used when determining the status for
the disease (affected/nonaffected) in an individual belong-
ing to an MJD family. In the control groups, the absence
of deaths that were attributable to a neurological disorder
could be explained by the fact that we were dealing with
small numbers, and not with the general population. From
the results mentioned above, and aiming at ascertaining the
status of the disease in deceased individuals belonging to
MJD families, we can establish the following categories, in
order of decreasing reliability: (1) MJD listed as cause of
death (corresponding to the most reliable category); (2)
other neurological diseases compatible with MJD (eg, ataxia,
tabes, sclerosis, or paralysis) listed as cause of death; and
(3) nonneurological disorders frequently associated with
MJD (eg, bronchopneumonia). According to our results,
the latter category cannot be used to confirm the presence
of the disease.
In conclusion, the fact that not more than nearly 40%
of the patients with clinically confirmed MJD had a cause
of death compatible with MJD precludes the use of cause
of death as a means of identifying affected individuals,
even in the large Azorean pedigrees. Although these re-
sults cannot be generalized to all the remaining popula-
tions, they should be taken into consideration in other
Portuguese cases. In the mainland of Portugal, where 34
families with MJD have been identified,17 new kindreds
have recently been described (P.C., oral communica-
tion, January 25, 1998). The genealogical reconstruc-
tion of these families is presently being undertaken. There-
fore, even if our study results are not generalizable, they
should provide further indications concerning the col-
lection of data for reconstructing previous generations
of the Portuguese MJD kindreds.
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